Список литературы

1. Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020 Jan; 76(1): 151 - 156. doi: 10.1111/his.13977.

2. Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019 Mar; 58(3): 342 - 352. doi: 10.1080/0284186X.2018.1540886.

3. Allison KH, Tenpenny E, Reed SD, Swisher EM, Garica RL. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol 2008; 16: 329-43.

4. Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, Kesterson J, et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020 Jun 15; 126(12): 2775 - 2783. doi: 10.1002/cncr.32822.

5. Габидуллина Р.И., Смирнова Г.А., Нухбала Ф.Р. и др. Гиперпластические процессы эндометрия: современная тактика ведения пациенток. Гинекология. 2019; 21 (6): 53 - 58. DOI: 10.26442/20795696.2019.6.190472.

6. Chandra V, Kim JJ, Benbrook DM, et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol 2016; 27: e8.

7. Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017 Mar 1; 23(2): 232 - 254. doi: 10.1093/humupd/dmw042.

8. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010 Feb 10; 28(5): 788-92. doi: 10.1200/JCO.2009.24.1315.

9. Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200. 678.e1-6.

10. Kurman R, Carcangiu M, Herrington C, Young R. World Health Organisation Classification of Tumors of Female Reproductive Organs, 4th edn Lyon France: International Agency for Research on Cancer (IARC) Press, 2014.

11. Tavassoli F, Devilee P (eds.). World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. IARC Press, Lyon 2003; 217 - 228.

12. Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 2017; 124: 404-11.

13. Raffone A, Travaglino A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet. 2019.

14. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol. 2000 Mar; 76(3): 287-90. doi: 10.1006/gyno.1999.5580.

15. Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol. 2015 May; 125(5): 1272-8. doi: 10.1097/01.AOG.00004.

16. Fraser IS, Critchley HO, Broder M, et al. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 2011; 29: 383-90.

17. Walker K, Decherney AH, Saunders R. Menstrual Dysfunction in PCOS. Clin Obstet Gynecol. 2021 Mar 1; 64(1): 119 - 125. doi: 10.1097/GRF.0000000000000596. PMID: 33481414.

18. Tian Y, Liu Y, Wang G, Lv Y, Zhang J, Bai X, et al. Endometrial hyperplasia in infertile women undergoing IVF/ICSI: A retrospective cross-sectional study. J Gynecol Obstet Hum Reprod. 2020 Apr 29: 101780. doi: 10.1016/j.jogoh.2020.101780.

19. Wise MR, Jordan V, Lagas A, Showell M, Wong N, Lensen S, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol 2016; 214: 689.e1 - 689.e17.

20. Beavis AL, Cheema S, Holschneider CH, et al. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep 2015; 13: 71-5.

21. Singh S, Best C, Dunn S, Leyland N, Wolfman WL; CLINICAL PRACTICE - GYNAECOLOGY COMMITTEE. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can. 2013 May; 35(5): 473 - 475. English, French. doi: 10.1016/S1701-2163(15) 30939-7. PMID: 237.

22. Heavy menstrual bleeding: assessment and management NICE guideline [NG88] Published date: 14 March 2018 Last updated: 31 March 2020.

23. ACOG Committee Opinion No. 426: The Role of Transvaginal ultrasonography in the Evaluation of Postmenopausal Bleeding Obstetrics & Gynecology: February 2009 - Volume 113 - Issue 2 Part 1 - p 462 - 464.

24. World Health Organization Classification of Tumors. WHO, 2003-14, P. 53 - 58.

25. HKCOG GUIDELINES NUMBER 16 (September 2015). Guidelines on Clinical Management of Endometrial Hyperplasia, published by The Hong Kong College of Obstetricians and Gynaecologists, A Foundation College of Hong Kong Academy of Medicine.

26. Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ, Sebastianelli A. Guideline No. 392-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 2019 Dec; 41(12): 1789 - 1800. doi: 10.1016/j.jogc.2019.03.025.

27. Gallos ID, Alazzam M, Clark T, Faraj R, Rosenthal A, Smith P GJ. RCOG Green-top Guideline: Management of Endometrial Hyperplasia. Royal College of Obstetricians & Gynaecologists. 2016.

28. Савельева Г.М. и др. Национальное руководство // Акушерство-М.: Гэотар-Медиа. - 2015.

29. Unim B. et al. Role of pap-test in cervical cancer prevention: a systematic review and meta-analysisBrigid Unim // European Journal of Public Health. - 2014. - Т. 24.

30. Schmidt, T., Breidenbach, M., Nawroth, F., Mallmann, P., Beyer, I. M., Fleisch, M. C., et al. Hysteroscopy for asymptomatic postmenopausal women with sonographically thickened endometrium. Maturitas, 2009, 62, 176 - 178.

31. Wanderley MD, lvares MM, Vogt MF, Sazaki LM. Accuracy of Transvaginal Ultrasonography, Hysteroscopy and Uterine Curettage in Evaluating Endometrial Pathologies. Rev Bras Ginecol Obstet. 2016 Oct; 38(10): 506 - 511. doi: 10.1055/s-0036-1593774. Epub 2016.

32. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound in Obstetrics and Gynecology, 2004, 24, 558-65.

33. Natarajan P, Vinturache A, Hutson R, Nugent D, Broadhead T. The value of MRI in management of endometrial hyperplasia with atypia. World J Surg Oncol. 2020 Feb 10; 18(1): 34. doi: 10.1186/s12957-020-1811-5.

34. Hwang WY, Suh DH, Kim K, No JH, Kim YB. Aspiration biopsy versus dilatation and curettage for endometrial hyperplasia prior to hysterectomy. Diagn Pathol. 2021 Jan 14; 16(1): 7. doi: 10.1186/s13000-020-01065-0. PMID: 33441173; PMCID: PMC7807457.

35. Lee N, Lee KB, Kim K, Hong JH, Yim GW, Seong SJ, Lee B, Lee JM, Cho J, Lim S, Ouh YT, Kim YB. Risk of occult atypical hyperplasia or cancer in women with nonatypical endometrial hyperplasia. J Obstet Gynaecol Res. 2020 Sep 17. doi: 10.1111/jog.14474.

36. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Committee Opinion No. 557. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013.

37. Bedner R, Rzepka-Gorska I. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. Eur J Gynaecol Oncol. 2007; 28(5): 400-2. PMID: 17966221.

38. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and meta-analysis of randomized trials. Am J Obstet Gynecol 2015; 213: 469-78.

39. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010.

40. El Behery MM, Saleh HS, Ibrahiem MA, Kamal EM, Kassem GA, Mohamed Mel S. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015 Mar; 22(3): 329-34. doi: 10.1177/19337.

41. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020 Sep 6; 9: CD012658. doi: 10.1002/14651858.CD012658.

42. Sletten ET, Arnes M, Lys LM, Larsen M, Orbo A. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study. BJOG. 2019 Jun; 126(7): 936-94.

43. Marra C, Penati C, Ferrari L, Cant MG, Bargossi L, Fruscio R. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses. Gynecol Endocrinol. 2014; 30(12): 899 - 901. doi: 10.3109/0951.

44. Адамян Л.В., ред. Сочетанные доброкачественные опухоли и гиперпластические процессы матки (миома, аденомиоз, гиперплазия эндометрия). Клинические рекомендации по ведению больных. М.; 2015.

45. Andreeva E, Absatarova Y. Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia. Int J Gynaecol Obstet. 2020 Dec; 151(3): 347 - 354. doi: 10.1002/ijgo.13341. Epub 2020 Sep 19. PMID: 32815156; PMCID: PMC7756.

46. Zhang Y, Sun L, Guo Y, Cheng J, Wang Y, Fan S, Duan H. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet Gynecol Surv. 2014 Feb; 69(2): 100-8. doi: 0.1097/OGX.000000000000.

47. Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V, Saravelos H, et al. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas. 2004 Jun 15; 48(2).

48. Dolapcioglu K, Boz A, Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study. Clin Exp Obstet Gynecol 2013; 40: 122-6.

49. Gallos ID, Krishan P, Shehmar M, et al. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013; 28: 1231-6.

50. Orbo A, Arnes M, Vereide AB, Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2016 Aug; 123(9): 1512-9. doi: 10.1111/1471-0528.13763.

51. Renaud MC, Le T. SOGC-GOC-SCC Policy and Practice Guidelines Committee. Epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can 2013; 35: 380-1.

52. Wise MR, Gill P, Lensen S, et al. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol 2016; 215. 598.e1-8.

53. Rosen MW, Tasset J, Kobernik EK, Smith YR, Johnston C, Quint EH. Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger. J Pediatr Adolesc Gynecol. 2019 Oct; 32(5): 546 - 549. doi: 10.1016/j.jpag.2019.06.004.

54. Evans EC, Matteson KA, Orejuela FJ, Alperin M, Balk EM, El-Nashar S, et al. Society of Gynecologic Surgeons Systematic Review Group. Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. Obstet Gynecol. 2016 Sep; 128(3): 476-85.

55. Mourits MJ, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010; 11: 763-71.

56. Galaal K, Bryant A, Fisher AD, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012; 9: CD006655.

57. Zapardiel I, Cruz M, Diestro MD, Requena A, Garcia-Velasco JA. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update. 2016 Apr; 22(3): 281 - 305. doi: 10.1093/humupd/dmv066. Epub 2016 Jan 12. PMID.

58. Cao DY, Yu M. Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin. Zhonghua Fu Chan Ke Za Zhi. 2013 Jul; 48(7).

59. Vetter MH, Smith B, Benedict J, Hade EM, Bixel K, Copeland LJ, et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. Am J Obstet Gynecol. 2020 Jan; 222(1):

60. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020 Apr 28; 15(4): e0232231. doi: 10.1371/.

61. Salvador S, Scott S, Francis JA, et al. No. 344-Opportunistic salpingectomy and other methods of risk reduction for ovarian/fallopian tube/peritoneal cancer in the general population. J Obstet Gynaecol Can 2017; 39: 480-93.

62. Antonsen SL, Ulrich L, Hogdall C. Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol 2012; 125: 124-8.

63. Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG. 2009 Jan; 116(1): 114.

64. Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: A systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207: 266.e.

65. Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V, Mariani A. Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021 Feb; 112(1): 55 - 69. doi: 10.23736/S0026-4806.20.07072-X. Epub 2020 Nov 18.

66. Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120: 1160-75.

67. Fernandez-Montoli ME, Sabadell J, Contreras-Perez NA. Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol. Adv Ther. 2021 Apr 8. doi: 10.1007/s12325-021-01693-y.

68. Simpson AN, Feigenberg T, Clarke BA, et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol 2014; 133: 229-33.

69. Kudesia R, Singer T, Caputo TA, et al. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. Am J Obstet Gynecol 2014; 210: 255.e14.

70. Koskas, M., Uzan, J. (2014). Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertility and Sterility, 101(3), 785 - 794.

71. Karlsson T, Johansson T, Hoglund J, Ek WE, Johansson. Time-Dependent Effects of Oral Contraceptive Use on Breast, Ovarian, and Endometrial Cancers. Cancer Res. 2021 Feb 15; 81(4): 1153 - 1162. doi: 10.1158/0008-5472.CAN-20-2476. Epub 2020 Dec 17.